Elizabeth R. Plimack

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 29 papers. Top paper: “Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial”.

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial

ESMO Open(2020)10.1136/esmoopen-2020-001079

N/A

6.4DataRank · unranked

524 citations

Nizar M. Tannir, Mauricio Burotto, David F. McDermott, Elizabeth R. Plimack, Philippe Barthélémy +15 more

Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2020-000891

N/A

5.8DataRank · unranked

225 citations

Bernard Escudier, David F. McDermott, Osvaldo Arén Frontera, Bohuslav Melichar, Thomas Powles +24 more

Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma

Cancer(2022)10.1002/cncr.34180

N/A

5.5DataRank · unranked

265 citations

David F. McDermott, Bernard Escudier, Mauricio Burotto, Toni K. Choueiri, Hans J. Hammers +20 more

Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer

Journal of Clinical Oncology(2020)10.1200/jco.19.01213

N/A

4.9DataRank · unranked

294 citations

Arjun Vasant Balar, Daniel Castellano, Peter H. O’Donnell, Petros Grivas, Joaquim Bellmunt +11 more

Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up

Annals of Oncology(2022)10.1016/j.annonc.2022.11.012

N/A

3.4DataRank · unranked

116 citations

Daniel Castellano, Petros Grivas, David J. Vaughn, Thomas Powles, Jacqueline Vuky +15 more

First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial

European Urology(2021)10.1016/j.eururo.2021.10.001

N/A

2.6DataRank · unranked

80 citations

Nizar M. Tannir, Mauricio Burotto, David F. McDermott, Elizabeth R. Plimack, Philippe Barthélémy +17 more

A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1)

Prostate Cancer and Prostatic Diseases(2022)10.1038/s41391-022-00492-y

N/A

0.873DataRank · unranked

22 citations

Nicole J. Toney, Renee N. Donahue, Susan Wróblewski, Matthew R. Zibelman, Pooja Ghatalia +9 more

Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2024-009495

N/A

0.615DataRank · unranked

19 citations

Opeyemi A. Jegede, Elizabeth R. Plimack, Thomas Powles, Robert J. Motzer, Nizar M. Tannir +13 more

Urine Biopsy as Dynamic Biomarker to Enhance Clinical Staging of Bladder Cancer in Radical Cystectomy Candidates

JCO Precision Oncology(2024)10.1200/po.23.00362

N/A

0.262DataRank · unranked

3 citations

Henkel Valentine, David Liu, Michael J. Slifker, Costas D. Lallas, Edouard J. Trabulsi +24 more

Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808

Clinical Genitourinary Cancer(2023)10.1016/j.clgc.2023.06.012

N/A

0.261DataRank · unranked

4 citations

Se Eun Kim, David F. McDermott, Janice P. Dutcher, Mäneka Puligandla, Judith Manola +10 more

Treatment-free survival (TFS) outcomes from the phase II study of nivolumab and salvage nivolumab + ipilimumab in advanced clear cell renal cell carcinoma (aRCC) (HCRN GU16-260-Cohort A).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.6_suppl.604

N/A

0DataRank · unranked

5 citations

Opeyemi A. Jegede, David F. McDermott, Naomi B. Haas, Mehmet Asım Bilen, Mark N. Stein +11 more

Effect of cerebral dopamine metabolism genetic polymorphism on patient-reported quality-of-life (QOL): An analysis of the E3805 CHAARTED trial.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.6_suppl.123

N/A

0DataRank · unranked

1 citations

Yu‐Hui Chen, Christopher Sweeney, David F. Jarrard, Elizabeth R. Plimack, Benjamin A. Gartrell +7 more

Metformin for biochemical recurrence of prostate cancer: Immune data from a phase 2 study.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.6_suppl.377

N/A

0DataRank · unranked

1 citations

Nicole J. Toney, Renee N. Donahue, Fatima Karzai, Ravi A. Madan, Jeffrey Schlom +8 more

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial

Annals of Oncology(2024)10.1016/j.annonc.2024.07.727

N/A

0DataRank · unranked

198 citations

Laurence Albigès, David F. McDermott, Mauricio Burotto, Toni K. Choueiri, Hans J. Hammers +20 more

Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2023-008293

N/A

0DataRank · unranked

6 citations

Opeyemi A. Jegede, Naomi B. Haas, David F. McDermott, Mehmet Asım Bilen, Mark N. Stein +11 more

Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma

Cancer Discovery(2025)10.1158/2159-8290.cd-24-0991

N/A

0DataRank · unranked

38 citations

Lena V. Wirth, Kelly Street, Neil Ruthen, Opeyemi A. Jegede, Nicholas R. Schindler +22 more

End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer

Journal of Clinical Oncology(2025)10.1200/jco-25-01608

N/A

0DataRank · unranked

16 citations

Matthew D. Galsky, Nazlı Dizman, David H. Aggen, Neeraj Agarwal, Hikmat Al‐Ahmadie +39 more

Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial

Annals of Oncology(2025)10.1016/j.annonc.2025.08.004

N/A

0DataRank · unranked

7 citations

Y. Chen, David F. Jarrard, Jorge A. García, R. Dreicer, Guoqiang Liu +12 more

Genetic Drivers of Quality of Life in Prostate Cancer: An Evaluation of Genetic Polymorphisms and Patient-reported Outcomes in the E3805 CHAARTED trial

European Urology Oncology(2025)10.1016/j.euo.2025.04.003

N/A

0DataRank · unranked

1 citations

Xiangying Chu, Charles J. Ryan, Arjun Gupta, Christopher J. Sweeney, David F. Jarrard +10 more

Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma 3574

The Journal of Immunology(2025)10.1093/jimmun/vkaf283.1362

N/A

0DataRank · unranked

0 citations

Miya B. Hugaboom, Kelly Street, Neil Ruthen, Opeyemi A. Jegede, Nicholas R. Schindler +22 more

Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial

Cancer(2020)10.1002/cncr.33033

N/A

0DataRank · unranked

340 citations

Bernard Escudier, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi +26 more

Assessing Contemporary Trends in Female Speakership within Urologic Oncology

Urology(2020)10.1016/j.urology.2020.08.006

N/A

0DataRank · unranked

15 citations

Adrien Bernstein, Amanda E. Jones, Juanita Crook, Andrea B. Apolo, Jennifer M. Taylor +7 more

Bicalutamide with or without metformin for biochemical recurrence in prostate cancer patients (BIMET-1).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.85

N/A

0DataRank · unranked

0 citations

Matthew R. Zibelman, Pooja Ghatalia, Susan Wróblewski, Ravi A. Madan, Fatima Karzai +5 more

Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2283

N/A

0DataRank · unranked

57 citations

Opeyemi A. Jegede, Charlene M. Mantia, Thomas Powles, Lillian Werner, Robert J. Motzer +16 more

Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma

European Urology(2021)10.1016/j.eururo.2021.12.003

N/A

0DataRank · unranked

13 citations

Akhilesh Mishra, Alana Christie, Tiffani McKenzie, Oreoluwa Onabolu, Nirmish Singla +12 more

S1314 correlative analysis of ATM, RB1, ERCC2, and FANCC mutations and pathologic complete response (pT0) at cystectomy after neoadjuvant chemotherapy (NAC) in patients with muscle invasive bladder cancer (MIBC): Implications for bladder preservation.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4581

N/A

0DataRank · unranked

7 citations

Catherine M. Tangen, Melissa Plets, Rutika Kokate, Joanne Xiu, Chadi Nabhan +9 more

A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study

European Urology(2023)10.1016/j.eururo.2023.01.017

N/A

0DataRank · unranked

56 citations

Michael A. O’Donnell, Jason A. Efstathiou, Marianna Zahurak, Gary L. Rosner, Jeff Smith +36 more

A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3642

N/A

0DataRank · unranked

38 citations

Galen Hostetter, Alexander W. Macfarlane, Zachary Madaj, Eric A. Ross, Toshinori Hinoue +22 more

Role of Gut Microbiome in Neoadjuvant Chemotherapy Response in Urothelial Carcinoma: A Multi-Institutional Prospective Cohort Evaluation

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.01.21.525021

N/A

0DataRank · unranked

7 citations

Rashida Ginwala, Mohit Sindhani, Megan Prunty, Daniel M. Geynisman, Pooja Ghatalia +15 more